Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,861 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mental Disorders, Severe Clear all
Enrolling by invitation No phase listed Observational

Mental Health, Intellectual and Neurodevelopmental Disorder Detection With Artificial Intelligence Models

NCT06792175
View directory record Official record
Conditions
Autism Spectrum Disorder, Depression - Major Depressive Disorder, Anxiety, Generalized, Bipolar Disorder (BD), Attention Deficit Hyperactivity Disorder (ADHD), Schizophrenia Spectrum &Amp; Other Psychotic Disorders, Post Traumatic Stress Disorder, Obsessive Compulsive Disorder (OCD)
Interventions
Solicue Machine Learning Models, Mercuria Machine Learning Models
Diagnostic Test
Lead sponsor
Psyrin Inc.
Industry
Eligibility
13 Years to 60 Years
Enrollment
500 participants
Timeline
2025 – 2026
U.S. locations
2
States / cities
Brookline, Massachusetts • Zanesville, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder

NCT01413932
View directory record Official record
Conditions
Healthy Volunteers (Part 1), Major Depressive Disorder (Part 2)
Interventions
HT-2157, Placebo
Drug
Lead sponsor
Dart NeuroScience, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Oct 19, 2026, 4:53 PM EDT
Recruiting Not applicable Interventional

Neurofeedback to Treat Depression - 2

NCT07159061
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Active Closed Loop Real Time fMRI Neurofeedback, Sham Closed Loop Real Time fMRI Neurofeedback
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Not applicable Interventional

Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings

NCT05030272
View directory record Official record
Conditions
Tobacco Use Disorder, Mental Illness, Recurring Major Depressive Disorder, Bipolar Disorder, Schizophrenia, Schizoaffective Disorder, Persistent Depressive Disorder
Interventions
Quit on the Go App (formerly "Learn to Quit " App), Brief advice, Nicotine patch, Smartphone coaching, Nicotine gum, Nicotine Lozenges
Device · Behavioral · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Buffalo, New York • Durham, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 19, 2026, 4:53 PM EDT
Recruiting Phase 2 Interventional

Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV

NCT05570812
View directory record Official record
Conditions
Major Depressive Disorder, Anxiety Depression, HIV
Interventions
Placebo, Pregnenolone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder

NCT00619619
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Little Rock, Arkansas • North Miami, Florida • Terre Haute, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Not applicable Interventional

Treatment for Depressed, Obese Individuals at Risk for Cardiovascular Disease (CVD)

NCT01692574
View directory record Official record
Conditions
Obesity, Major Depressive Disorder, Dysthymic Disorder, Cardiovascular Disease
Interventions
Behavior Modification for Weight Loss, Alternative Approach to Weight Loss, Cognitive-Behavior Therapy for Depression, Depression Support and Education
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2016 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 4 Interventional Results available

AndroGel in Men With Major Depression and Incomplete Response to Antidepressant Treatment

NCT00304746
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Testosterone gel, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
30 Years to 65 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2010 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Not applicable Interventional Results available

Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults

NCT05384041
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Fisher Wallace Cranial Electrotherapy Stimulator (Active Device), Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device)
Device
Lead sponsor
Fisher Wallace Laboratories
Industry
Eligibility
21 Years to 65 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 3 Interventional

An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder

NCT00629551
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
saredutant (SR48968), paroxetine, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 4 Interventional

Interpersonal Therapy for Depression in Breast Cancer

NCT01191580
View directory record Official record
Conditions
Major Depression
Interventions
Interpersonal Psychotherapy, Problem-Solving Therapy, Brief Supportive Psychotherapy
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 90 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 2 Interventional

Pilot Decentralized Trial

NCT05419869
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALTO-100 PO Tablet
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
18 Years to 64 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Coral Gables, Florida • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 2 Interventional

An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder

NCT00057239
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Radafaxine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
29
States / cities
Little Rock, Arkansas • Newport Beach, California • Farmington, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2010 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Smoking Cessation for Veterans With Severe and Persistent Mental Illness

NCT00960375
View directory record Official record
Conditions
Schizoaffective Disorder, Schizophrenia, Affective Psychosis, Bipolar, Affective Disorders, Psychotic
Interventions
BTSCS, StSST
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 75 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Not applicable Interventional

The RAFT ECT Study

NCT05402657
View directory record Official record
Conditions
Major Depressive Episode
Interventions
Frontoparietal Ultrabrief Right Unilateral (UBRUL-FP) electroconvulsive therapy, Temporoparietal Ultrabrief Right Unilateral (UBRUL-TP) electroconvulsive therapy
Procedure
Lead sponsor
The George Institute
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia • Augusta, Georgia • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 19, 2026, 4:53 PM EDT
Recruiting Phase 2 Interventional

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

NCT07284667
View directory record Official record
Conditions
Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
Interventions
ACP-211, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
28
States / cities
Birmingham, Alabama • Chino, California • Glendale, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Not applicable Interventional Results available

Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD

NCT02634177
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Assay-guided treatment (AGT), Treatment-as-usual (TAU)
Genetic · Other
Lead sponsor
Genomind, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Springdale, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 19, 2026, 4:53 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Imaging SV2A in Mood Disorders

NCT02734602
View directory record Official record
Conditions
Major Depressive Disorder, Post-Traumatic Stress Disorder
Interventions
Ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 2 Interventional

To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.

NCT06429722
View directory record Official record
Conditions
Major Depressive Episode Associated With Bipolar II Disorder
Interventions
NMRA-335140 80 mg, Placebo
Drug
Lead sponsor
Neumora Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
21
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Garden Grove, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 19, 2026, 4:53 PM EDT
Terminated Phase 1 Interventional

Alexithymia Intervention for Suicide

NCT05724953
View directory record Official record
Conditions
Suicide, Schizophrenia, Bipolar Disorder, Post Traumatic Stress Disorder, Major Depressive Disorder
Interventions
Affective Awareness
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder

NCT00252330
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SR58611A
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 4 Interventional Results available

Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study

NCT01668667
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
GSK1838262 600 mg, GSK1838262 450 mg, GSK1838262 300 mg, GSK1838262 Placebo match
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
42
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PET Imaging of mGLuR5 With Drug Challenge

NCT01691092
View directory record Official record
Conditions
Major Depressive Disorder, Post-Traumatic Stress Disorder (PTSD)
Interventions
Ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
3
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 2 Interventional Results available

A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

NCT00840034
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
LY2216684, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Carson, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 19, 2026, 4:53 PM EDT